Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype 1 patients support development of Omega DUROS(R) continuous delivery therapy

WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of final results from a Phase 2 study comparing the combination of injectable omega interferon and ribavirin to omega interferon alone in treatment-naive patients with genotype 1 chronic hepatitis C. The results demonstrate that omega interferon in combination with ribavirin is well tolerated and shows robust antiviral activity that is comparable to published data on the use of alpha interferon plus ribavirin in similar patient populations. The 72-week sustained viral response (SVR) data are being presented today at the Digestive Disease Week Conference in Washington, DC by Bruce R. Bacon, MD, Professor of Internal Medicine, Saint Louis University Medical Center, St. Louis, Missouri.

This Phase 2 study of daily subcutaneous omega interferon injections provides Intarcia with safety and clinical response data to support development of omega interferon delivered by continuous release from the DUROS(R) device.

"The safety and SVR rates achieved in this phase 2 study are encouraging in that they indicate that the combination of omega interferon and ribavirin may produce response rates which are similar to those achieved with alpha interferon and ribavirin in patients with HCV genotype-1," said Dr. Bacon. "The positive results of this study allow us to proceed with the evaluation of continuous delivery of omega interferon delivered with the DUROS device. A trial evaluating dose response of the Omega DUROS device is expected to begin in the near future."

The Phase 2 trial compared the safety and antiviral response of omega interferon alone with omega interferon in combination with ribavirin in 102 interferon-na
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/31/2014)... July 31, 2014  Zacks.com announces the list of stocks ... Research analysts discuss the latest news and events impacting stocks ... include the Biogen (Nasdaq: BIIB - Free Report ), Gilead ... PBYI - Free Report ), AbbVie (NYSE: ABBV ... Free Report ). Today, Zacks is promoting its ...
(Date:7/31/2014)... YORK , July 31, 2014 TB ... better, faster and affordable treatments for tuberculosis (TB), announced ... Vice President, Market Access. Ms. Robertson joins the organization ... company,s business in Sub-Saharan Africa and Eastern ... oversee the TB Alliance,s efforts to ensure beneficial new ...
(Date:7/31/2014)... und KISSING, Deutschland, 31. Juli ... und Distributor eines computerunterstützten („robotischen") Koloskopie-Systems für ... (Homi) Shamir , ein weltweit anerkannter Manager ... und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener globaler Visionär ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3
... 4, 2011 Bioness Inc. today ... of the FASTEST study to further examine the impact of ... drop as a result of stroke. The FASTEST study aims ... System over standard therapy with an ankle-foot orthosis (AFO), and ...
... Inc. (NASDAQ: NBIX ) today announced that it ... for elagolix and next-generation Gonadotropin Releasing Hormone (GnRH) Receptor Antagonists. ... with the FDA, the outcome of which generated a $20 ... event brings the total milestones achieved by the Company in ...
Cached Medicine Technology:Bioness Inc. Announces Completion of Enrollment in Its FASTEST L300 Study 2Neurocrine Biosciences Receives Second Milestone Payment of $20 Million Under Abbott Collaboration Agreement 2
(Date:7/31/2014)... Longmont, Colo. (PRWEB) July 31, 2014 ... snacks, has launched three new products including: a Cacao Nib ... Like all Two Moms in the Raw products, each is ... , “My family is picky, so I’m constantly working on ... our consumers more healthy and tasty choices,” said Shari Leidich, ...
(Date:7/31/2014)... Ohio Presbyterian Retirement Services (OPRS) announced that ... Center, Inc. (Sarah Moore HCC) has joined its family ... Sarah Moore HCC was established in 1892 as a home ... has grown and developed an excellent reputation for high-quality assisted ... has been an integral part of the Delaware community for ...
(Date:7/31/2014)... Francsico, CA (PRWEB) July 31, 2014 ... Sweden have published the largest study ... triage through either teledermoscopy or traditional letter referral ... that smartphone referrals via patent pending iDoc24® technology ... patients with skin cancer while potentially eliminating unnecessary ...
(Date:7/31/2014)... Glaser Pediatric AIDS Foundation (EGPAF) and Riders for ... the delivery of laboratory samples and HIV-related test ... the Northern and Central Zones of Malawi. ... will establish a dependable and coordinated system to ... in health services for the more than 1.3 ...
(Date:7/31/2014)... Delhi, India (PRWEB) July 31, 2014 ... special service for those individuals and organizations against whom ... service as ‘Remove Negative Comments Service’. , About ... said, “We have officially announced the service now, but ... get rid of negative comments for several years.” , ...
Breaking Medicine News(10 mins):Health News:Two Moms in the Raw Launches Three New, Raw, Sprouted 100% Organic Snacks 2Health News:Two Moms in the Raw Launches Three New, Raw, Sprouted 100% Organic Snacks 3Health News:Ohio Presbyterian Retirement Services Welcomes The Sarah Moore HCC into Its Family 2Health News:Ohio Presbyterian Retirement Services Welcomes The Sarah Moore HCC into Its Family 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 2Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 3Health News:Smartphone iDoc 24 Technology Speeds Time to Diagnosis and Treatment for Skin Cancer Patients 4Health News:Elizabeth Glaser Pediatric AIDS Foundation partners with Riders for Health in Malawi 2Health News:RankingBySEO Launches a New Service ‘Remove Negative Comments’ 2
... must stop tippling if they want to recover from ... that researched the brain's capacity to regenerate.// ... provides evidence that excessive drinking for a long period ... portal EurekAlert. ,During abstinence, an alcoholic's brain ...
... and literature to spread awareness about the importance of ... including 6,000 women scholars, will be appointed to spread ... said Chaudhry Shahbaz Hussain, federal population planning minister. ... students also aware of these norms, he said. ...
... next-generation medical technology, in conjunction with MYOTECH//, LLC, ... the potential of the MYO-VAD, a cardiac support ... failure. The MYO-VAD restores cardiac output on an ... implanted in approximately three minutes. ,Researchers found ...
... Supermarket chains are recalling some brands of frozen ready meals ... Eye meals//, because of fears that they may contain small ... thousands of ready meals. ,The products came ... Group. Rye Valley foods are one of the country's biggest ...
... from the Italian court, presiding over a milestone case regarding ... paralyzed and terminally ill – who has petitioned the court ... and allow him to die. ,Italy, largely influenced ... and the case has stirred a hornet’s nest, where euthanasia ...
... cells have the ability to trace damaged tissue in the ... on mice.// ,This finding is of great interest ... the human brain, and this knowledge can be put to ... disorders such as traumatic injury. ,Dr. Chay Kuo, ...
Cached Medicine News:Health News:Positive Animal Study on MYO-VAD, Promise for Treatment of Heart Failure 2Health News:Stem Cells In Brain Have Potential For Sensing Damage And To Repair 2
Hand surgery basic instrument set with round handled instruments...
Rhoton microscopic forceps, straight...
Quick release, easy to close 2" webbing and buckle. Available in teal, royal, red, purple, and maroon nylon stain-resistant fabric or navy nylon reinforced vinyl....
Velcro closures on each side to more evenly distribute the weight. Available in teal, royal, red, purple, or maroon nylon stain-resistant fabric or navy nylon reinforced vinyl....
Medicine Products: